Could a protein blocker quiet Leukemia's alarm system?

NCT ID NCT07741695

Not yet recruiting Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study investigates whether blocking a protein called IRAK4 can disrupt TLR signaling in leukemia cells from people with chronic lymphocytic leukemia (CLL). Researchers will collect extra blood samples from 50 adults with CLL during routine blood tests. In the lab, they will expose the leukemia cells to an IRAK4-degrading drug and measure changes in key signaling molecules. The goal is to understand if this approach could be a potential treatment target.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IRAK4 CDAC (a drug that degrades IRAK4, tested in the lab on blood samples)
What this could lead to: If IRAK4 blockade disrupts TLR signaling in CLL cells, it could point toward a new targeted treatment for chronic lymphocytic leukemia.
What could go wrong: This is a lab-based study on blood samples, not a treatment trial, so results may not translate into a real therapy. The drug is not being given to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

More trials for these conditions

Other studies related to the condition(s) this trial covers.